Please login to the form below

Not currently logged in
Email:
Password:

Corlanor

This page shows the latest Corlanor news and features for those working in and with pharma, biotech and healthcare.

Amgen agrees to take Cytokinetics' heart failure drug into phase III

Amgen agrees to take Cytokinetics' heart failure drug into phase III

It sits among a new generation of heart failure therapies - spearheaded by Novartis' Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) - which are trying to advance the treatment of heart

Latest news

  • FDA clears Amgen's Corlaner for heart failure FDA clears Amgen's Corlaner for heart failure

    Corlaner's approval is based on the results of the phase III SHIFT trial, which compared Corlanor to placebo, in addition to standard of care, in more than 6500 patients. ... Corlanor is thought to work by decreasing heart rate and represents the first

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics